InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: None

Friday, 01/28/2022 12:05:00 PM

Friday, January 28, 2022 12:05:00 PM

Post# of 4159
data accrued to date for the TLD 1433-2 open label study for
$TLTFF
The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon. Dr. Vera Madzarevic Director Clinical Development & Quality Assurance, Theralase® NOVEMBER 2021

JMO, maybe, maybe not.